Novel Oral Anticoagulants at 10: An Assessment of their Safety and Contemporary Use in Atrial Fibrillation
Published: 04 March 2021
In this virtual roundtable, our expert panel reflect on the clinical trials and real world data supporting the use of NOACs in atrial fibrillation – almost ten years since they entered the clinic.
Moderated by Prof John Eikelboom, the panel offer their analyses via a series of presentations and discussions covering a range of topics, with a special focus on their use in Japan.
- Identify which individuals with atrial fibrillation should be initiated on NOAC therapy without delay
- Interpret safety and cardiovascular data from RCTs in the context of real-world experience
- Select appropriate treatment strategies with NOACs in atrial fibrillation patients in need of further ablation or intervention
- Review the reversal options open to individuals experiencing a bleeding event whilst on treatment with a NOAC
- Interventional Cardiologists
More from this programme
When to Initiate a NOAC and Patient Suitability (data presentation)
Overview of Safety and Cardiovascular Data
Dealing with Complications:
Discussion on Safety Rates and Patient Suitability (Panel Discussion Session)
NOAC Use with Ablation and Intervention
Dr John Eikelboom is an Associate Professor in the Department of Medicine at McMaster University in Hamilton , Ontario .
Dr Eikelboom earned his MBBS degree at the University of Western Australia Medical School, Australia and he completed training in Internal Medicine and Haematology at Royal Perth Hospital , Australia and trained in Epidemiology and Thrombosis Medicine at McMaster University .
Dr Eikelboom’s current research focuses on variable response to antiplatelet therapy, antithrombotic therapy in atrial fibrillation, and mechanisms and prognosis of bleeding. He has published more than 150 peer-reviewed papers. He is a member of the Editorial Board for Stroke and on the Advisory Board for the Journal of Thrombosis and Haemostasis.